BTC Capital Management Inc. Boosts Stock Position in Gilead Sciences, Inc. $GILD

BTC Capital Management Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 119.3% in the third quarter, Holdings Channel reports. The firm owned 118,862 shares of the biopharmaceutical company’s stock after purchasing an additional 64,668 shares during the period. BTC Capital Management Inc.’s holdings in Gilead Sciences were worth $13,192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC grew its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the period. Mutual Advisors LLC increased its position in Gilead Sciences by 16.9% in the second quarter. Mutual Advisors LLC now owns 21,228 shares of the biopharmaceutical company’s stock worth $2,467,000 after buying an additional 3,072 shares during the last quarter. Finally, WealthPlan Investment Management LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at $344,000. 83.67% of the stock is currently owned by institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Price Performance

GILD stock opened at $154.98 on Friday. The firm has a 50 day moving average of $130.27 and a 200-day moving average of $122.27. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The firm has a market capitalization of $192.28 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GILD. Deutsche Bank Aktiengesellschaft increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Mizuho lifted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $152.42.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 319,391 shares of company stock valued at $44,141,101 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.